Clinical trial · Interventional
Empirical Radioactive Iodine Therapy in DTC
Efficacy of Empirical Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma Patients With Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) Syndrome
NCT07453225CI-TRIAL-00104749not yet recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is assessment the efficacy of empiric RAI therapy in DTC patients with elevated thyroglobulin levels and negative iodine scintigraphy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Differentiated Thyroid Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radioactive Iodine Therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- patients received empirical dose of RAI
- description
- patients treated with empirical dose
- interventionNames
- Drug: Radioactive Iodine Therapy
- type
- NO_INTERVENTION
- label
- patients didn't receive empirical dose of RAI
- description
- patients monitored without empirical RAI dose
Primary outcomes (1)
- measure
- efficacy of empirical radioactive iodine therapy
- timeFrame
- 2 years
- description
- by assessment of tumor marker (serum thyroglobulin ) if decreased after empirical therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * This study will include adult patients with pathologically proved DTC who underwent total thyroidectomy and received RAI therapy presented to our nuclear medicine unit with evidence of persistent or recurrent biochemical disease during follow up. Exclusion Criteria: * Undifferentiated thyroid cancer. * Patients with evidence of structural disease. * Patients less than 18 years old.
References
Publications (0)
Data not yet available
No reference posted for this study.